New discoveries by scientists at Auckland University, have resulted in a substantial trans-Tasman licensing agreement to develop a potential world-first treatment for osteoporosis.
The bone-thinning disease is now reaching epidemic proportions, particularly among women and the elderly, says UniServices intellectual property manager, Johanna Stapelberg.
If the development of the new drugs is successful, it could lead to significant royalties to the university.
The new drug appears to be free of side effects, and stops bone loss and promotes bone-cell growth.